Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IMDUR vs BIDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Combination of isosorbide dinitrate (a nitric oxide donor) and hydralazine (a direct vasodilator). Isosorbide dinitrate relaxes vascular smooth muscle via NO-mediated c GMP production; hydralazine reduces peripheral resistance and may inhibit DNA synthesis in endothelial cells. Synergy enhances vasodilation and improves cardiac output.
Prevention of angina pectoris due to coronary artery disease,Off-label: chronic heart failure (as adjunctive therapy), esophageal spasm
Heart failure: treatment to improve survival, prolong time to hospitalization, and improve quality of life in self-identified black patients with heart failure (NYHA class III-IV) receiving standard therapy (diuretics, ACE inhibitors/ARBs, beta-blockers). Off-label: none significant.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
Isosorbide dinitrate 20 mg plus hydralazine 37.5 mg orally three times daily; titrate to target dose of isosorbide dinitrate 40 mg plus hydralazine 75 mg three times daily as tolerated.
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); isosorbide dinitrate: 1 hour (parent), 4-5 hours (isosorbide-5-mononitrate, active metabolite). Clinical context: Requires twice-daily dosing for sustained effect.
Primarily hepatic metabolism via denitration and glucuronidation; isosorbide mononitrate is the active metabolite of isosorbide dinitrate and does not undergo significant first-pass metabolism.
Isosorbide dinitrate: extensively metabolized by denitration and conjugation in the liver; hydralazine: primarily metabolized by N-acetylation (N-acetyltransferase 2, NAT2) and subsequent glucuronidation.
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Hydralazine: 80% renal (as active drug and metabolites, predominantly N-acetylhydralazine and hydralazine pyruvic acid hydrazone); isosorbide dinitrate: renal (metabolites, primarily isosorbide mononitrates and isosorbide) and fecal (minor).
Less than 5%, primarily to albumin. Very low protein binding, which contributes to high free fraction.
Hydralazine: 87-90% (plasma proteins); isosorbide dinitrate: 30-40% (albumin).
Volume of distribution is approximately 0.6-0.7 L/kg for isosorbide mononitrate. This moderate Vd indicates distribution into total body water and some tissue binding.
Hydralazine: 1.6 L/kg; isosorbide dinitrate: 2-4 L/kg. Clinical meaning: Extensive tissue distribution for both components.
Oral bioavailability is nearly 100% for isosorbide mononitrate due to lack of first-pass metabolism (unlike isosorbide dinitrate). For IMDUR extended-release, relative bioavailability is comparable to immediate-release, with controlled release properties.
Hydralazine: 30-50% (oral, first-pass effect); isosorbide dinitrate: 20-30% (oral, extensive first-pass metabolism).
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution; consider starting at 30 mg once daily and titrate slowly.
No specific dose adjustment recommended; however, hydralazine is cleared renally and may accumulate in severe renal impairment (Cr Cl <30 m L/min); consider monitoring for adverse effects.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%; start at 30 mg once daily. Child-Pugh Class C: Contraindicated or use with extreme caution; start at 30 mg once daily with careful monitoring.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment but caution advised due to potential increased exposure.
Not approved for pediatric use. Limited data: 0.5-2 mg/kg orally once daily, not to exceed 120 mg once daily.
Safety and efficacy not established in pediatric patients; no standard dosing recommendations available.
Start at 30 mg once daily; titrate slowly due to increased sensitivity and risk of hypotension.
Initiate at lower end of dosing range; titrate slowly due to increased risk of hypotension and dizziness; monitor renal function as hydralazine clearance may decrease.
Not recommended for use in patients with acute myocardial infarction (MI) or congestive heart failure (CHF) requiring rapid hemodynamic monitoring; use only under close clinical observation.
None.
Hypotension: may cause severe hypotension, especially with upright posture,Tolerance: continuous use may lead to tolerance and cross-tolerance to other nitrates; use with a daily nitrate-free interval,Headache: often occurs but may diminish with continued use,Glaucoma: controversial; generally considered safe,Volume depletion: increased risk of hypotension
Hypotension (monitor blood pressure), agranulocytosis (rare; hydralazine may cause neutropenia; monitor CBC), drug-induced lupus-like syndrome (hydralazine; discontinue if symptoms develop), hepatotoxicity (hydralazine; monitor liver enzymes), risk of syncope when initiating or increasing dose, volume depletion (correct before use).
Hypersensitivity to isosorbide mononitrate or other nitrates,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Acute circulatory failure or shock
Hypersensitivity to hydralazine or isosorbide dinitrate, severe hypotension (<100 mm Hg systolic), acute myocardial infarction (safety not established), cardiogenic shock, cardiomyopathy with restrictive/obstructive physiology, use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Avoid high-fat meals as they may delay absorption. No specific food interactions; alcohol may increase hypotensive effects.
No specific food interactions. Avoid excessive alcohol intake as it may exacerbate hypotension.
FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: No specific malformation pattern identified. Second and third trimesters: Potential risk of fetal hypotension and reduced placental perfusion due to maternal vasodilation.
FDA Pregnancy Category C. First trimester: Animal studies show fetal harm; no adequate human studies. Second and third trimesters: Hydralazine crosses placenta; may cause fetal hypotension, thrombocytopenia. Isosorbide dinitrate: Limited data; associated with methemoglobinemia in neonates. Use only if benefit outweighs risk.
Unknown if isosorbide mononitrate is excreted in human breast milk. M/P ratio not established. Caution advised; consider discontinuing nursing or drug, balancing importance of drug to mother.
Hydralazine is excreted in breast milk (M/P ratio ~1.2); low levels unlikely to harm infant. Isosorbide dinitrate: No data on excretion. Monitor infant for hypotension. American Academy of Pediatrics considers hydralazine compatible with breastfeeding.
No specific dose adjustments recommended for pregnancy; however, hemodynamic changes (increased plasma volume, cardiac output) may alter pharmacokinetics. Start at lowest effective dose and titrate based on maternal response and tolerability.
Pregnancy may increase volume of distribution and clearance of hydralazine; dose adjustments may be needed to maintain efficacy. Isosorbide dinitrate: no specific recommendations; start at lowest effective dose and titrate based on blood pressure response. Monitor for orthostatic hypotension.
Imdur (isosorbide mononitrate) is an extended-release nitrate used for angina prophylaxis. Avoid concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Tachyphylaxis can occur with continuous use; maintain a daily nitrate-free interval (typically 10-12 hours) to preserve efficacy. Do not crush or chew extended-release tablets. Monitor blood pressure and heart rate during initiation. Use with caution in patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, or volume depletion.
Bidil is a fixed-dose combination of isosorbide dinitrate (20 mg) and hydralazine (37.5 mg), indicated as an adjunct to standard therapy for heart failure in self-identified African American patients (NYHA class III-IV, left ventricular ejection fraction <45%). Dizziness and headache are common due to vasodilation; titrate slowly. Avoid use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Monitor for fluid retention and worsening heart failure. Consider dose reduction in hepatic impairment.
Take Imdur exactly as prescribed, usually once daily in the morning to maintain a nitrate-free interval.,Do not crush, chew, or cut the tablet; swallow it whole with a glass of water.,Avoid taking erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on Imdur, as this can cause a dangerous drop in blood pressure.,If you experience headache, it may indicate the drug is working; acetaminophen can help. Inform your doctor if headaches persist.,Store at room temperature, away from moisture and heat.
Take this medication exactly as prescribed, usually three times daily with or without food.,Do not take with erectile dysfunction drugs (e.g., Viagra, Cialis, Levitra) as this can cause a dangerous drop in blood pressure.,Common side effects include dizziness and headache, which may improve over time; report severe or persistent symptoms to your doctor.,Avoid sudden position changes to prevent falls.,Do not stop taking this medication abruptly without consulting your healthcare provider.,Inform all healthcare providers you are taking Bidil.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IMDUR vs BIDIL, answered by our medical review team.
IMDUR is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. BIDIL is a Vasodilator Combination that works by Combination of isosorbide dinitrate (a nitric oxide donor) and hydralazine (a direct vasodilator). Isosorbide dinitrate relaxes vascular smooth muscle via NO-mediated c GMP production; hydralazine reduces peripheral resistance and may inhibit DNA synthesis in endothelial cells. Synergy enhances vasodilation and improves cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IMDUR and BIDIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IMDUR is: Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.. The standard adult dose of BIDIL is: Isosorbide dinitrate 20 mg plus hydralazine 37.5 mg orally three times daily; titrate to target dose of isosorbide dinitrate 40 mg plus hydralazine 75 mg three times daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IMDUR and BIDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IMDUR is classified as Category C. FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies . BIDIL is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal harm; no adequate human studies. Second and third trimesters: Hydralazine crosses placenta; may cause fetal hyp. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.